PT Phapros Tbk

peha

+0.61%

Overview

PEHA Overview

PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.

2468101214ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: PEHA

Main
Market Cap.
IDR 275.52Billion

~$16.92M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

PEHA Valuation Metrics

328

IDR
+0.6%

Closing Price on 2024-06-14

Price to Equity

-9.77

P/E

At -9.77x P/E TTM, PEHA.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

0.38

P/B

At 0.38x P/B TTM, PEHA.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

0.30

P/S

At 0.30x P/S TTM, PEHA.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Valuing PT Phapros Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Phapros Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
6.00x
Price/Forward Earnings
-
Enterprise Value/Revenue
1.10x
Enterprise Value/EBITDA
20.50x
PEG Ratio
0.01x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR3282024-06-14
IDR 186.54

Considerably Lower Intrinsic Value: Analyst's intrinsic value is of PEHA is IDR187, which is 42% lower than PEHA's last closing price of IDR328 (as of 2024-06-14).

Valuation Recap of PEHA stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -9.77x is below the ID market average of 8.07x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (9.96x). In fact, less than 25% of its peers trade at a lower P/E ratio than PEHA.

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 0.38x is below the peers average of 1.17x in the Pharmaceuticals & Health Care Research sector. In fact, less than 25% of its peers trade at a lower P/B ratio than PEHA.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.30x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of PEHA's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. PEHA's P/CF ratio of 6.00x is considered healthy by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. PEHA's EV/R ratio of 1.10x is considered extremely underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.10x.

Medium
Considerably Lower Intrinsic Value: Analyst's intrinsic value is of PEHA is IDR 186.54, which is 42% lower than PEHA's last closing price of IDR 328.00.

Peers

PEHA Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.39T28.96T 30.94T 2.87T 25.243.23
MIKAPT Mitra Keluarga Karyasehat Tbk.41.72T7.81T 4.48T 0.97T 42.826.83
SILOPT Siloam International Hospitals Tbk.33.75T11.42T 11.56T 0.98T 34.614.27
SRAJSejahteraraya Anugrahjaya Tbk26.40T5.62T 2.71T -0.02T -1327.5114.19
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk22.20T4.25T 3.71T 1.04T 21.335.85
HEALPT Medikaloka Hermina Tbk.20.03T9.20T 6.14T 0.52T 38.564.80
TSPCTempo Scan Pacific Tbk8.97T11.93T 13.33T 1.02T 8.831.11
PRAYPT Famon Awal Bros Sedaya Tbk8.86T4.81T 1.93T 0.21T 43.073.08
SOHOPT Soho Global Health Tbk8.63T5.13T 8.58T 0.44T 19.583.42
KAEFKimia Farma Tbk.3.26T17.59T 9.97T -1.49T -2.190.72
Competitiveness Recap of PEHA stock
WeightNotesScore
High
At a market cap of IDR 275.52 billion, PEHA.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of -9.77, PEHA.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -110.33 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (43.07) in the Healthcare sector.

Medium
At a PE of -9.77, PEHA.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 9.96). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.

Medium
At a revenue of IDR 0.92 trillion, PEHA.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of -IDR 0.03 trillion, PEHA.JK ranks 10 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of PEHA

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 14.72% against the IDX average of +13.1%.

Pharmaceuticals & Health Care Research sector overview
No data is available for PEHA at the moment.
Future growth prospect of PEHA
WeightNotesScore
High
PEHA's projected growth rate of 14.72% is above the ID market average of 13.14%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 15.82% in 2025. This number is higher than the previous year 2024's growth rate of 7.04%. This bodes well for PEHA's revenue growth prospects in the next 2 years.

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 24.87% in 2025. This number is higher than the previous year 2024's EPS growth of 12.80%. This bodes well for PEHA's earnings growth prospects in the next 2 years.

Medium
PEHA and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 22.74% in 2025 while revenue growth is projected to increase by 20.17%. These macroeconomic trends will likely be a tailwind for PEHA's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

-15.2 years
David E.S. Sidjabat
Director
Maraja Jeson Siregar
Director
Ida Rahmi Kurniasih
Director
Nurtjahjo Walujo Wibowo
Director
NamePositionShares%
Masrizal A. SyariefCommissioner86,057,75010.24
Expressed in millions IDR, unless otherwise stated

Ownership

PEHA Ownership

NameNumber of SharesOwnership (%)Value
Pt Kimia Farma Tbk476,901,86056.77156.42B
Public (Scripless)252,062,49030.0182.68B
Masrizal A. Syarief86,057,75010.2428.23B
Public (Scrip)24,977,9002.978.19B
No data is available for PEHA at the moment.

    Sectors, Indonesia's Financial Data Layer

    We hate spam as much as you do. We do not resell your data.

    Email us at sectors@supertype.ai for enquiries on using Sectors for your business or organization.

    © 2024 Supertype Pte. Ltd.
    (and subsidiary PT. Supertype Teknologi Nusantara)